LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: How does face mask in COVID-19 pandemic disrupt face learning and recognition in adults with autism spectrum disorder?

    Tso, Ricky V / Chui, Celine O / Hsiao, Janet H

    Cognitive research: principles and implications

    2022  Volume 7, Issue 1, Page(s) 64

    Abstract: Use of face masks is one of the measures adopted by the general community to stop the transmission of disease during this ongoing COVID-19 pandemic. This wide use of face masks has indeed been shown to disrupt day-to-day face recognition. People with ... ...

    Abstract Use of face masks is one of the measures adopted by the general community to stop the transmission of disease during this ongoing COVID-19 pandemic. This wide use of face masks has indeed been shown to disrupt day-to-day face recognition. People with autism spectrum disorder (ASD) often have predisposed impairment in face recognition and are expected to be more vulnerable to this disruption in face recognition. Here, we recruited typically developing adult participants and those with ASD, and we measured their non-verbal intelligence, autism spectrum quotient, empathy quotient, and recognition performances of faces with and without a face mask covering the lower halves of the face. When faces were initially learned unobstructed, we showed that participants had a general reduced face recognition performance for masked faces. In contrast, when masked faces were first learned, typically developing adults benefit with an overall advantage in recognizing both masked and unmasked faces; while adults with ASD recognized unmasked faces with a significantly more reduced level of performance than masked faces-this face recognition discrepancy is predicted by a higher level of autistic traits. This paper also discusses how autistic traits influence processing of faces with and without face masks.
    MeSH term(s) Adult ; Autism Spectrum Disorder ; COVID-19 ; Humans ; Masks ; Pandemics ; Recognition, Psychology
    Language English
    Publishing date 2022-07-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2365-7464
    ISSN (online) 2365-7464
    DOI 10.1186/s41235-022-00407-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Importance of Face Masks for COVID-19: A Call for Effective Public Education.

    Tso, Ricky V / Cowling, Benjamin J

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 71, Issue 16, Page(s) 2195–2198

    Abstract: Considerable debates about the general community use of face masks for protection against coronavirus disease 2019 (COVID-19) stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face masks ... ...

    Abstract Considerable debates about the general community use of face masks for protection against coronavirus disease 2019 (COVID-19) stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face masks may hinder the containment of the COVID-19 pandemic. We address this previous debate by analyzing the advice on the community use of masks across different credible health authorities: countries that promoted the use of masks acknowledged that masks are effective but also explained the importance of their proper use along with other hygiene measures. In contrast, authorities that recommended against the community use of masks mainly cited shortage of supplies, the argument that the public do not have the adequate skills to wear them, or that wearing masks might reduce compliance with other important behaviors. We suggest promoting effective behavioral changes in personal protective measures by teaching microbiological knowledge instead of just listing out the "do's-and-don'ts."
    MeSH term(s) COVID-19/prevention & control ; Health Education/methods ; Health Knowledge, Attitudes, Practice ; Humans ; Hygiene ; Masks ; Public Health/methods ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-07-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa593
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Importance of face masks for COVID-19 - a call for effective public education

    Tso, Ricky V / Cowling, Benjamin J

    Clin. infect. dis

    Abstract: Considerable debates about the general community use of face masks for protection against COVID-19 stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face masks may hinder the containment of ...

    Abstract Considerable debates about the general community use of face masks for protection against COVID-19 stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face masks may hinder the containment of the COVID-19 pandemic. We address this previous debate by analyzing the advice on the community use of masks across different credible health authorities: countries that promoted the use of masks acknowledged that masks are effective, but also explained the importance of their proper use along with other hygiene measures. In contrast, authorities that recommended against the community use of masks mainly cited shortage of supplies, the argument that the public do not have the adequate skills to wear them, or that wearing masks might reduce compliance with other important behaviors. We suggest promoting effective behavioral changes in personal protective measures by teaching microbiological knowledge instead of just listing out the "dos-and-don'ts".
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #625339
    Database COVID19

    Kategorien

  4. Article ; Online: Importance of Face Masks for COVID-19

    Tso, Ricky V / Cowling, Benjamin J

    Clinical Infectious Diseases ; ISSN 1058-4838 1537-6591

    A Call for Effective Public Education

    2020  

    Abstract: Abstract Considerable debates about the general community use of face masks for protection against coronavirus disease 2019 (COVID-19) stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face ...

    Abstract Abstract Considerable debates about the general community use of face masks for protection against coronavirus disease 2019 (COVID-19) stemmed out from differing views taken by health authorities. Misconceptions and stigmatization towards the use of face masks may hinder the containment of the COVID-19 pandemic. We address this previous debate by analyzing the advice on the community use of masks across different credible health authorities: countries that promoted the use of masks acknowledged that masks are effective but also explained the importance of their proper use along with other hygiene measures. In contrast, authorities that recommended against the community use of masks mainly cited shortage of supplies, the argument that the public do not have the adequate skills to wear them, or that wearing masks might reduce compliance with other important behaviors. We suggest promoting effective behavioral changes in personal protective measures by teaching microbiological knowledge instead of just listing out the “do’s-and-don’ts.”
    Keywords Microbiology (medical) ; Infectious Diseases ; covid19
    Language English
    Publisher Oxford University Press (OUP)
    Publishing country uk
    Document type Article ; Online
    DOI 10.1093/cid/ciaa593
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

    Hung, Ivan Fan-Ngai / Lung, Kwok-Cheung / Tso, Eugene Yuk-Keung / Liu, Raymond / Chung, Tom Wai-Hin / Chu, Man-Yee / Ng, Yuk-Yung / Lo, Jenny / Chan, Jacky / Tam, Anthony Raymond / Shum, Hoi-Ping / Chan, Veronica / Wu, Alan Ka-Lun / Sin, Kit-Man / Leung, Wai-Shing / Law, Wai-Lam / Lung, David Christopher / Sin, Simon / Yeung, Pauline /
    Yip, Cyril Chik-Yan / Zhang, Ricky Ruiqi / Fung, Agnes Yim-Fong / Yan, Erica Yuen-Wing / Leung, Kit-Hang / Ip, Jonathan Daniel / Chu, Allen Wing-Ho / Chan, Wan-Mui / Ng, Anthony Chin-Ki / Lee, Rodney / Fung, Kitty / Yeung, Alwin / Wu, Tak-Chiu / Chan, Johnny Wai-Man / Yan, Wing-Wah / Chan, Wai-Ming / Chan, Jasper Fuk-Woo / Lie, Albert Kwok-Wai / Tsang, Owen Tak-Yin / Cheng, Vincent Chi-Chung / Que, Tak-Lun / Lau, Chak-Sing / Chan, Kwok-Hung / To, Kelvin Kai-Wang / Yuen, Kwok-Yung

    Lancet (London, England)

    2020  Volume 395, Issue 10238, Page(s) 1695–1704

    Abstract: Background: Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID- ... ...

    Abstract Background: Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.
    Methods: This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688.
    Findings: Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4·37 [95% CI 1·86-10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis. No patients died during the study.
    Interpretation: Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.
    Funding: The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.
    MeSH term(s) Adult ; Betacoronavirus ; Coronavirus Infections/drug therapy ; Drug Combinations ; Drug Therapy, Combination ; Female ; Hong Kong ; Hospitalization ; Humans ; Interferon beta-1b/therapeutic use ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/drug therapy ; Ribavirin/therapeutic use ; Ritonavir/therapeutic use
    Chemical Substances Drug Combinations ; lopinavir-ritonavir drug combination ; Interferon beta-1b (145155-23-3) ; Lopinavir (2494G1JF75) ; Ribavirin (49717AWG6K) ; Ritonavir (O3J8G9O825)
    Keywords covid19
    Language English
    Publishing date 2020-05-10
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(20)31042-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

    Hung, Ivan Fan-Ngai / Lung, Kwok-Cheung / Tso, Eugene Yuk-Keung / Liu, Raymond / Chung, Tom Wai-Hin / Chu, Man-Yee / Ng, Yuk-Yung / Lo, Jenny / Chan, Jacky / Tam, Anthony Raymond / Shum, Hoi-Ping / Chan, Veronica / Wu, Alan Ka-Lun / Sin, Kit-Man / Leung, Wai-Shing / Law, Wai-Lam / Lung, David Christopher / Sin, Simon / Yeung, Pauline /
    Yip, Cyril Chik-Yan / Zhang, Ricky Ruiqi / Fung, Agnes Yim-Fong / Yan, Erica Yuen-Wing / Leung, Kit-Hang / Ip, Jonathan Daniel / Chu, Allen Wing-Ho / Chan, Wan-Mui / Ng, Anthony Chin-Ki / Lee, Rodney / Fung, Kitty / Yeung, Alwin / Wu, Tak-Chiu / Chan, Johnny Wai-Man / Yan, Wing-Wah / Chan, Wai-Ming / Chan, Jasper Fuk-Woo / Lie, Albert Kwok-Wai / Tsang, Owen Tak-Yin / Cheng, Vincent Chi-Chung / Que, Tak-Lun / Lau, Chak-Sing / Chan, Kwok-Hung / To, Kelvin Kai-Wang / Yuen, Kwok-Yung

    Lancet

    Abstract: BACKGROUND: Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19. ...

    Abstract BACKGROUND: Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19. METHODS: This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688. FINDINGS: Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4·37 [95% CI 1·86-10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis. No patients died during the study. INTERPRETATION: Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted. FUNDING: The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #232479
    Database COVID19

    Kategorien

  7. Article ; Online: Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19

    Hung, Ivan Fan-Ngai / Lung, Kwok-Cheung / Tso, Eugene Yuk-Keung / Liu, Raymond / Chung, Tom Wai-Hin / Chu, Man-Yee / Ng, Yuk-Yung / Lo, Jenny / Chan, Jacky / Tam, Anthony Raymond / Shum, Hoi-Ping / Chan, Veronica / Wu, Alan Ka-Lun / Sin, Kit-Man / Leung, Wai-Shing / Law, Wai-Lam / Lung, David Christopher / Sin, Simon / Yeung, Pauline /
    Yip, Cyril Chik-Yan / Zhang, Ricky Ruiqi / Fung, Agnes Yim-Fong / Yan, Erica Yuen-Wing / Leung, Kit-Hang / Ip, Jonathan Daniel / Chu, Allen Wing-Ho / Chan, Wan-Mui / Ng, Anthony Chin-Ki / Lee, Rodney / Fung, Kitty / Yeung, Alwin / Wu, Tak-Chiu / Chan, Johnny Wai-Man / Yan, Wing-Wah / Chan, Wai-Ming / Chan, Jasper Fuk-Woo / Lie, Albert Kwok-Wai / Tsang, Owen Tak-Yin / Cheng, Vincent Chi-Chung / Que, Tak-Lun / Lau, Chak-Sing / Chan, Kwok-Hung / To, Kelvin Kai-Wang / Yuen, Kwok-Yung

    The Lancet

    an open-label, randomised, phase 2 trial

    2020  Volume 395, Issue 10238, Page(s) 1695–1704

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/s0140-6736(20)31042-4
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top